Related Experiment Video

Updated: Aug 17, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis

Sunil K Halder1, R Daniel Beauchamp, Pran K Datta

  • 1Department of Surgery, Vanderbilt University School of Medicine, 1161 21st Avenue South, D5230 MCN, Nashville, TN 37232, USA.

Experimental Cell Research
|June 1, 2005
PubMed

Insights

Smad7 protein blocks transforming growth factor beta (TGF-beta) signaling in colon cancer cells. This blockade promotes cell growth and survival, potentially increasing tumor development by making cells resistant to TGF-beta

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Smad proteins are key intracellular mediators of transforming growth factor beta (TGF-beta) superfamily signaling.
  • Smad7 acts as an intracellular antagonist of TGF-beta signaling and is often upregulated in various cancers.
  • TGF-beta signaling plays a crucial role in regulating diverse biological processes, including cell growth and apoptosis.

Purpose of the Study:

  • To investigate the functional consequences of Smad7-mediated blockade of TGF-beta signaling in human colon adenocarcinoma cells.
  • To elucidate the molecular mechanisms by which Smad7 influences TGF-beta-induced cellular responses.

Main Methods:

  • Stable expression of Smad7 in TGF-beta-sensitive FET human colon adenocarcinoma cells.
  • Analysis of TGF-beta-induced transcriptional responses, Smad complex formation, and signaling pathway activation (MAPK, Akt, c-Jun).
  • Assessment of cellular phenotypes including anchorage-independent growth, tumorigenicity in vivo, cell cycle progression, apoptosis, and expression of key regulatory proteins.

Main Results:

  • Smad7 expression inhibited TGF-beta-induced transcriptional responses by blocking Smad2/3-Smad4 complex formation.
  • Smad7 blocked TGF-beta-induced Akt phosphorylation and G1 arrest, while enhancing c-Jun phosphorylation.
  • FET cells expressing Smad7 exhibited increased anchorage-independent growth, enhanced tumorigenicity, and resistance to TGF-beta-induced apoptosis and growth inhibition.

Conclusions:

  • Smad7 antagonizes TGF-beta's tumor-suppressive functions by inhibiting growth arrest and apoptosis in colon cancer cells.
  • Smad7-mediated blockade of TGF-beta signaling contributes to increased tumorigenicity, offering a potential mechanism for colorectal tumor refractoriness to TGF-beta.
  • Targeting Smad7 or restoring TGF-beta pathway sensitivity could be a therapeutic strategy for colorectal cancers.

More Related Videos

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System11:06

Live Cell Imaging of the TGF- β/Smad3 Signaling Pathway In Vitro and In Vivo Using an Adenovirus Reporter System

Published on: July 30, 2018

Spheroid Assay to Measure TGF-β-induced Invasion09:18

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...